Free Trial

AIM ImmunoTech (AIM) Stock Price, News & Analysis

+0.02 (+5.15%)
(As of 01:36 PM ET)
Today's Range
50-Day Range
52-Week Range
291,196 shs
Average Volume
236,878 shs
Market Capitalization
$20.73 million
P/E Ratio
Dividend Yield
Price Target
AIM stock logo

About AIM ImmunoTech Stock (NYSE:AIM)

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM Stock Price History

AIM Stock News Headlines

Q1 2024 AIM ImmunoTech Inc Earnings Call
AIM Completes Ampligen Turnout
See More Headlines
Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.20 per share


Free Float
Market Cap
$19.71 million
Not Optionable

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Thomas K. Equels Esq.Mr. Thomas K. Equels Esq. (Age 71)
    J.D., M.S., Executive Vice Chairman, CEO & President
    Comp: $953.19k
  • Mr. Robert Dickey IV (Age 68)
    M.B.A., Chief Financial Officer
    Comp: $64.48k
  • Mr. Peter W. Rodino III (Age 73)
    Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary
    Comp: $484.94k
  • Ann Marie E. Coverly
    Director of Administration & Human Resources and Deputy Investor Relations Coordinator
  • Dr. Carol A. Smith (Age 73)
    Chief Manufacturing Officer & Deputy Chief Scientific Officer
    Comp: $170.77k
  • Dr. Christopher McAleer Ph.D.
    Scientific Officer
  • Dr. Ralph Christopher Cavalli Ph.D. (Age 66)
    Vice President of QC & Manufacturing
    Comp: $234.79k

AIM Stock Analysis - Frequently Asked Questions

How have AIM shares performed in 2024?

AIM ImmunoTech's stock was trading at $0.4399 on January 1st, 2024. Since then, AIM stock has decreased by 8.5% and is now trading at $0.4025.
View the best growth stocks for 2024 here

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) issued its quarterly earnings results on Thursday, May, 16th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $0.04 million for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 191.38% and a negative net margin of 16,123.32%.

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

How do I buy shares of AIM ImmunoTech?

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AIM) was last updated on 6/13/2024 by Staff

From Our Partners